NOVOMEDLINK™

This page contains information about Novo Nordisk products.

NovoLog®—designed to
mimic the normal physiologic
insulin profile1

Patients with type 2 diabetes who are taking basal insulin may find that their A1C remains elevated even when their fasting blood glucose levels are on target. This may result from inadequately controlled glucose spikes after meals.

Patients in this situation may be able to improve glycemic control by adding mealtime bolus doses of a rapid-acting insulin analog. Combined with daily basal insulin, mealtime bolus injections can help ensure glycemic needs are met throughout the day.

Bolus insulin provides coverage for mealtime spikes in blood glucose

The basal-bolus principle

The basal-bolus principle
eView-video.png

Learn more about bolus dosing with NovoLog® in “Take On the Mealtime Challenge with a Rapid-Acting Insulin Analog,” presented by Dr. Helen Baron

View eDetail

NovoLog® mimics the body's normal mealtime insulin response1

NovoLog® is a rapid-acting insulin analog that is engineered for mealtime use. Compared with subcutaneously administered regular human insulin, NovoLog® has a faster onset of action, an earlier and higher peak concentration, and a shorter duration of action. NovoLog® can help control mealtime glucose spikes, without the “long tail” of regular human insulin.2-4

NovoLog pharmacokinetics2

NovoLog pharmacokinetics

Mean free serum insulin concentrations collected in 22 patients with type 1 diabetes for up to 6 hours following a single dose of NovoLog® injected before a meal versus regular human insulin injected immediately before a meal.2

Adapted from Lindholm et al, 1999.

NovoLog® has a more rapid onset and shorter duration of
action than regular human insulin

Onset of action:

  • 10 to 20 minutes for NovoLog® versus 30 minutes for regular human insulin

Peak concentration:

  • 40 to 50 minutes for NovoLog® versus 80 to 120 minutes for regular human insulin

Duration of action:

  • 3 to 5 hours for NovoLog® versus up to 8 hours for regular human insulin
callout eView Video

Having better conversations with your patients

Explaining how NovoLog® works in patient-friendly terms

Watch MOA video

Related Support

View eSeminar Watch a clinical overview of the efficacy, safety, and tolerability of
NovoLog® for patients with type 1 diabetes.

Play audio program Learn about mealtime glucose control and how a rapid-acting
insulin analog may help.

Up Next

See how NovoLog® provides better mean postprandial glucose (PPG) levels versus regular human insulin5,6

References:

  1. Brange J, Vølund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev. 1999;35(2-3):307-335.
  2. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart: a randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 1999;22(5):801-805.
  3. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol. 1999;55(3):199-203.
  4. Skyler J. Insulin treatment. In: American Diabetes Association. Therapy for Diabetes Mellitus and Related Disorders. 5th ed. Alexandria, VA: American Diabetes Association; 2009.
  5. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23(5):583-588.
  6. Data on file, Novo Nordisk, Inc., Princeton, NJ.

  1. NovoLog® (insulin aspart [rDNA origin] injection) Indications and Usage

    NovoLog® is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

    NovoLog® Important Safety Information

    NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

    NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent. Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulins.

    Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity.

    Needles and NovoLog® FlexPen® must not be shared.

    NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes under the age of two.

    Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog®. Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment.

    Please click hereclick here for Prescribing Information.

FlexPen® and NovoLog® are registered trademarks of Novo Nordisk A/S.
NovoMedLink™ is a trademark of Novo Nordisk A/S.
This is presented in Macromedia Flash. If you don't have the proper plug-in, you can download it free by clicking here